---
title: "Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Indication questions"
description: "Indication questions on Paxlovid (nirmatrelvir; ritonavir) in COVID-19, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What is Paxlovid approved for? Can Paxlovid be used to prevent COVID-19 after exposure? Is Paxlovid approved for people without COVID-19 risk factors? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/paxlovid--covid-19/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Paxlovid (nirmatrelvir; ritonavir) in COVID-19: Indication questions

Manufacturer: Pfizer Inc  
Prescribing information: [Paxlovid](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599)

Indication questions that apply to every indication of Paxlovid are on [Paxlovid (nirmatrelvir; ritonavir), all indications: Indication](https://www.evicenter.com/medical-information/paxlovid/indication).

## Indication

<a id="paxlovid-indication"></a>

### What is Paxlovid approved for?

> “PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=PAXLOVID%20is%20indicated%20for%20the,COVID%2D19%2C%20including%20hospitalization%20or%20death.)

> “PAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19 [see Clinical Studies (14.3)].”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=PAXLOVID%20is%20not%20approved%20for%20use%20as%20pre%2Dexposure%20or%20post%2Dexposure%20prophylaxis%20for%20prevention%20of%20COVID%2D19%20%5Bsee%20Clinical%20Studies%20%2814.3%29%5D.,-2%20DOSAGE%20AND)

<a id="paxlovid-post-exposure-prevention"></a>

### Can Paxlovid be used to prevent COVID-19 after exposure?

> “PAXLOVID is not indicated for the post-exposure prophylaxis of COVID-19.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=PAXLOVID%20is%20not%20indicated%20for%20the%20post%2Dexposure%20prophylaxis%20of%20COVID%2D19.)

> “In a double-blind, double-dummy, placebo-controlled trial, the efficacy of PAXLOVID when administered for 5 or 10 days as post-exposure prophylaxis of COVID-19 was evaluated. Eligible subjects were asymptomatic adults 18 years of age and older who were SARS-CoV-2 negative at baseline and who lived in the same household with symptomatic individuals with a recent diagnosis of SARS-CoV-2. A total of 2,736 subjects were randomized (1:1:1) to receive PAXLOVID orally every 12 hours for 5 days, PAXLOVID orally every 12 hours for 10 days, or placebo.
>
> The primary endpoint for this trial was not met. The primary endpoint was the risk reduction between the 5-day and 10-day PAXLOVID regimens versus placebo in the proportion of subjects who developed RT-PCR or RAT-confirmed symptomatic SARS-CoV-2 infection through Day 14 who had a negative SARS-CoV-2 RT-PCR result at baseline. The proportion of subjects who had events through Day 14 was 2.6% for the 5-day PAXLOVID regimen, 2.4% for the 10-day PAXLOVID regimen, and 3.9% for placebo. There was not a statistically significant risk reduction versus placebo for either the 5-day or 10-day PAXLOVID regimen.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=In%20a%20double%2Dblind%2C%20double%2Ddummy%2C%20placebo%2Dcontrolled,5%2Dday%20or%2010%2Dday%20PAXLOVID%20regimen.)

<a id="paxlovid-standard-risk"></a>

### Is Paxlovid approved for people without COVID-19 risk factors?

> “PAXLOVID is not indicated for the treatment of COVID-19 in patients without a risk factor for progression to severe COVID-19.”

Source: [PAXLOVID: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=19599#:~:text=PAXLOVID%20is%20not%20indicated%20for,for%20progression%20to%20severe%20COVID%2D19.)

## Related pages
- [Medical information: Paxlovid (nirmatrelvir; ritonavir): COVID-19](https://www.evicenter.com/medical-information/paxlovid--covid-19)
- [Clinical trials](https://www.evicenter.com/medical-information/paxlovid--covid-19/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/paxlovid--covid-19/real-world-evidence)
- [Safety](https://www.evicenter.com/medical-information/paxlovid--covid-19/safety)
- [Specific populations](https://www.evicenter.com/medical-information/paxlovid--covid-19/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/paxlovid--covid-19/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/paxlovid--covid-19/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/paxlovid--covid-19/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/paxlovid--covid-19/guidelines)
